A big drugmaker is backing away from a plan to triple the price of a lifesaving cancer drug after facing a public backlash
|05/15/2018||Posted by BusinessMediaguide.Com under General World News||
- Drugmaker Pharmacyclics had tripled the cost of a lifesaving cancer blood treatment when it introduced a new version of the pill.
- The new price tag faced criticism from cancer doctors who were concerned about how this would impact how they dosed patients with the drug.
- Last week, Pharmacyclics reversed its decision to take the initial version of the drug off the market, giving patients and doctors a lower-cost option.
The maker of a lifesaving blood cancer treatment planned to triple the cost of the drug — but it’s backing down after pressure from doctors.
The drug, Imbruvica, treats serious forms of read more >>>